These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3492701)

  • 21. [Surveillance of Pseudomonas aeruginosa sensitivity to antibiotics in France and distribution of beta-lactam resistance mechanisms: 1998 GERPB study].
    Cavallo JD; Leblanc F; Fabre R
    Pathol Biol (Paris); 2000 Jun; 48(5):472-7. PubMed ID: 10949844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
    Aghazadeh M; Hojabri Z; Mahdian R; Nahaei MR; Rahmati M; Hojabri T; Pirzadeh T; Pajand O
    Infect Genet Evol; 2014 Jun; 24():187-92. PubMed ID: 24694825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis.
    Simpson IN; Finlay J; Winstanley DJ; Dewhurst N; Nelson JW; Butler SL; Govan JR
    J Antimicrob Chemother; 1994 Sep; 34(3):353-61. PubMed ID: 7530242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic and genetic resistance traits of Pseudomonas aeruginosa strains infecting cystic fibrosis patients: A French cohort study.
    Courtois N; Caspar Y; Maurin M
    Int J Antimicrob Agents; 2018 Sep; 52(3):358-364. PubMed ID: 29775685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
    Livermore DM; Mushtaq S; Ge Y; Warner M
    Int J Antimicrob Agents; 2009 Nov; 34(5):402-6. PubMed ID: 19428220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
    Mushtaq S; Warner M; Livermore DM
    J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
    Cantón R; Valdezate S; Vindel A; Sánchez Del Saz B; Maíz L; Baquero F
    Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation and partial purification of a carbapenem-hydrolysing metallo-beta-lactamase from Pseudomonas cepacia.
    Baxter IA; Lambert PA
    FEMS Microbiol Lett; 1994 Oct; 122(3):251-6. PubMed ID: 7527361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients.
    Sherrard LJ; Schaible B; Graham KA; McGrath SJ; McIlreavey L; Hatch J; Wolfgang MC; Muhlebach MS; Gilpin DF; Schneiders T; Elborn JS; Tunney MM
    J Antimicrob Chemother; 2014 Oct; 69(10):2690-8. PubMed ID: 24917582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Metallo-β-lactamase Producing Non-fermentative Pseudomonas Species from Clinical Isolates in Dhaka, Bangladesh.
    Islam MN; Ahmed D; Hossain MA; Ahsan CR; Yasmin M
    Mymensingh Med J; 2018 Jan; 27(1):89-94. PubMed ID: 29459597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis.
    Gilligan PH; Gage PA; Bradshaw LM; Schidlow DV; DeCicco BT
    J Clin Microbiol; 1985 Jul; 22(1):5-8. PubMed ID: 4019742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of beta-lactamase production in Pseudomonas maltophilia, a nosocomial pathogen.
    Cullmann W; Dick W
    Chemotherapy; 1990; 36(2):117-26. PubMed ID: 2311440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas.
    Blumer JL; Stern RC; Klinger JD; Yamashita TS; Meyers CM; Blum A; Reed MD
    Am J Med; 1985 Aug; 79(2A):37-46. PubMed ID: 3895917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.
    Isles A; Maclusky I; Corey M; Gold R; Prober C; Fleming P; Levison H
    J Pediatr; 1984 Feb; 104(2):206-10. PubMed ID: 6420530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial properties of investigational, new, and commonly used antibiotics against isolates of Pseudomonas cepacia in Michigan.
    Bhakta DR; Leader I; Jacobson R; Robinson-Dunn B; Honicky RE; Kumar A
    Chemotherapy; 1992; 38(5):319-23. PubMed ID: 1283733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    Antimicrob Agents Chemother; 1984 Feb; 25(2):279-80. PubMed ID: 6561954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.
    Papp-Wallace KM; Becka SA; Taracila MA; Zeiser ET; Gatta JA; LiPuma JJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Li Y; Zhang X; Wang C; Hu Y; Niu X; Pei D; He Z; Bi Y
    Mol Med Rep; 2015 Jan; 11(1):494-8. PubMed ID: 25323940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.